Summary of Significant Accounting Policies (Tables)
|
6 Months Ended |
Jun. 30, 2026 |
|---|
| Accounting Policies [Abstract] |
|
| Schedule of Inventory |
At
June 30, 2026 and December 31, 2025, inventory was as follows:
Schedule of Inventory
| Classification | |
June 30, 2026 | | |
December 31, 2025 | |
| Finished systems | |
$ | 918,352 | | |
$ | 1,256,862 | |
| Less: writedown of inventory to net realizable value | |
| (238,352 | ) | |
| (576,862 | ) |
| Total Inventory | |
$ | 680,000 | | |
$ | 680,000 | |
|
| Schedule of Deposits |
Deposits
represent amounts paid to a third-party manufacturer toward the purchase of a PET-CT system, the recoverability of which is contingent
upon successful equipment validation and U.S. Food and Drug Administration (FDA) clearance. Activity in deposits for the six months
ended June 30, 2026 and the year ended December 31, 2025 was as follows:
Schedule of Deposits
| December 31, 2024 | |
$ | 375,000 | |
| No activity | |
| - | |
| December 31, 2025 | |
$ | 375,000 | |
| No activity | |
| - | |
| June 30, 2026 | |
$ | 375,000 | |
|
| Schedule of Company’s revenues disaggregated |
The
following table presents the Company’s revenues disaggregated by type for the six months ended June 30, 2026 and 2025:
| Schedule of Company’s revenues disaggregated | |
Three Months Ended June 30, | |
| | |
2026 | | |
2025 | |
| | |
| | |
| | |
| | |
| |
| Sales | |
Revenue | | |
% of Revenues | | |
Revenue | | |
% of Revenues | |
| | |
| | | |
| | | |
| | | |
| | |
| Service Income | |
$ | 111,822 | | |
| 100 | % | |
$ | 120,118 | | |
| 100 | % |
| Total Revenues | |
$ | 111,822 | | |
| 100 | % | |
$ | 120,118 | | |
| 100 | % |
Schedule of Company’s revenues disaggregated
| | |
Six Months Ended June 30, | |
| | |
2026 | | |
2025 | |
| | |
| | |
| | |
| | |
| |
| Sales | |
Revenue
| | |
% of Revenues | | |
Revenue | | |
% of Revenues | |
| | |
| | | |
| | | |
| | | |
| | |
| Service Income | |
$ | 222,822 | | |
| 100 | % | |
$ | 239,452 | | |
| 100 | % |
| Total Revenues | |
$ | 222,822 | | |
| 100 | % | |
$ | 239,452 | | |
| 100 | % |
|
| Schedule of deferred revenue |
At
June 30, 2026 and December 31, 2025, deferred revenue consisted of the following:
Schedule of deferred revenue
| Type | |
June 30, 2026 | | |
December 31, 2025 | |
| Customer deposit - equipment sale | |
$ | 210,000 | | |
$ | 70,000 | |
| Customer deposit - other | |
| - | | |
| 50,000 | |
| Total deferred revenue | |
$ | 210,000 | | |
$ | 120,000 | |
|
| Schedule of marketing and advertising costs |
The
Company recognized marketing and advertising costs as follows:
Schedule of marketing and advertising costs
| Three Months Ended June 30, | |
| 2026 | | |
2025 | |
| | | |
| |
| $ | 98,255 | | |
$ | 40,737 | |
| Six Months Ended June 30, | |
| 2026 | | |
2025 | |
| | | |
| |
| $ | 164,920 | | |
$ | 125,285 | |
|
| Schedule of potentially dilutive equity securities outstanding |
The
following potentially dilutive equity securities outstanding as of June 30, 2026 and 2025 were as follows:
Schedule of potentially dilutive equity securities outstanding
| | |
June 30, 2026 | | |
June 30, 2025 | |
| Stock Options | |
| 5,150,000 | | |
| - | |
| Warrants | |
| 2,100,000 | | |
| 2,100,000 | |
| Series A, convertible preferred stock | |
| - | | |
| 1,088 | |
| Series B, convertible preferred stock | |
| - | | |
| 48,000 | |
| Total common stock equivalents | |
| 7,250,000 | | |
| 2,149,088 | |
|